CABA May 2024 15.000 put
| Previous Close | 3.6200 |
| Open | 2.6000 |
| Bid | 0.9000 |
| Ask | 4.1000 |
| Strike | 15.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 2.6000 - 2.6000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2.19k |
GlobeNewswireCabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– No CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials – – Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials to be presented at a satellite symposium at the EULAR 2024 Congress in June – – Evaluating CABA-201 without preconditioning by initiation of the RESET-PV™ sub-study within the ongoing DesCAARTes™ trial in pemphigus vulga
- GlobeNewswire
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
PHILADELPHIA, May 13, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on Monday, May 20, 2024 at 9:30 a.m. ET in New York, NY. A live webcast of the presentation wi
GuruFocus.comCabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
Q4 and Full Year 2023 Financial Results Reveal Strategic Advancements in Autoimmune Therapies
